Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
Key facts
- Who runs it
- University of Iowa
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 12 Jun 2025
- Expected to end
- Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Psilocybin
- Ketamine
- Record updated
- 28 November 2025
Who can take part
- Age
- 21 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (20)Hide the full registry criteria
Who can take part
- Weight between 50kg and 150kg
- No known allergies to rescue medication
- For people capable of becoming pregnant, not pregnant and using contraception
- Not currently breastfeeding
- Meets criteria for DSM-V moderate to severe AUD
- Have at least 4 heavy drinking days (5 or more standard drinks in a day) in the past 30 days
- Not currently participating in formal treatment for AUD
- No history of a of cerebrovascular accident, asthma, or significant alcohol withdrawal history
- No seizure disorder, coronary artery disease, heart failure, uncontrolled hypertension, insulin-dependent diabetes, pancreatitis, liver disease
- No hallucinogen or ketamine use in past 12 months
- No self-reported, personal, or familial history of specific psychotic disorders/episodes
- No serious traumatic brain injury (TBI) in the past 2 years
- No substance use disorder other than AUD over the past 12 months
- If taking a GLP-1 agonist, stable dosage for past 3 months
- Family member/friend for pick-up, overnight post-drug session monitoring
- No MRI contraindications
Who cannot take part
- Drug/medication assessment that yields: nonprescription medication use, nutritional supplement, or herbal supplement (except when approved by the study investigators), medically unstable, current medication use that has significant potential to interact with study drug (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants, or benzodiazepines)
- Psychiatric assessment that yields:1) history of severe suicide attempt, 2) current suicidality 3) first-degree relative with schizophrenia or schizoaffective disorder, 4) comorbid substance use disorder including cocaine, psychostimulant, or opioid use disorder within past 12 months 5) history of co-occurring psychotic episode/diagnosis including schizophrenia, schizoaffective disorder, schizophreniform, substance-induced psychosis, delusional disorder, or psychosis not otherwise specified, 6) high risk of adverse emotional or behavioral reaction based on the medical monitor's clinical evaluation that may also yield evidence of serious current stressors, a lack of meaningful social support, antisocial behavior, and/or serious personality disorders amongst other conditions
- Medical assessment that yields: serious ECG abnormalities (evidence of ischemia, myocardial infarction, QTc prolongation [QTc > .045]), serious abnormalities of complete blood count or chemistries, medical conditions that would preclude safe participation (significantly impaired liver function), or pregnancy
- MRI contraindication (pacemaker, etc.)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Alcohol use disorder or alcohol dependence or alcohol abuse
This trial is currently available in United States.
- University of Iowa Health CareIowa City, United StatesContact: Lindsay E GoldenTaking people
About the trial
What the trial wants to find out
This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.
The 2 groups in the trial
- Psilocybin Group (Arm 1)Treatment being tested
receives individual psychotherapy sessions plus a (30 mg) psilocybin session.
Treatment: Psilocybin
- Ketamine Group (Arm 2)Existing treatment, for comparison
receives individual psychotherapy sessions plus a (0.75 mg/kg) ketamine session
Treatment: Ketamine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Psilocybin vs Ketamine for Alcohol Use Disorder
- Criteria questions
- Built from NCT06405607, who can take part
- Record updated
- 28 November 2025